Cascadian Therapeutics announces proposed concurrent public offerings of common stock
Cascadian Therapeutics announced it intends to offer and sell shares of its common stock and Series E convertible preferred stock in concurrent but separate underwritten public offerings. The Series E convertible preferred stock is non-voting and convertible into shares of Cascadian common stock. January 23, 2017